NCT06646055View on ClinicalTrials.gov

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, Cadonilimab, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

AK112, nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

DRUG

nab-paclitaxel, gemcitabine

IV infusion, specified dose on specified days.

Trial Locations (1)

Unknown

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology., Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT06646055 - AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter